Business
Preclinical Data for SRA737 in Ovarian Cancer
Preclinical Data for SRA737 in Ovarian Cancer.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 4818H Sareum Holdings PLC 15 November 2018 \n\n\n\n\n(AIM: SAR)\n\n\n15 November 2018\n\n\n\n \nSareum Holdings plc\n(\"Sareum\" or \"the Company\")\nSierra Oncology Reports Supportive Preclinical Data for SRA737 in Ovarian Cancer Models\nSareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, has today reported new preclinical data that support its ongoing clinical trial with SRA737 as a monotherapy in ovarian cancer. The data were presented in a poster at the 30th EORTC-NCI-AACR Symposium currently being held in Dublin, Ireland.\nAs reported in the poster:\n· Chk1 inhibition by SRA737 shows promising efficacy in CCNE1-amplified and MYCN overexpressing preclinical models of high-grade serous ovarian cancer (HGSOC) \n· The in vivo data support the ongoing monotherapy clinical trial of SRA737, which includes the prospective enrolment of patients with these HGSOC subtypes \n· Furthermore, the preclinical data suggest that the exploration of potential combination regimens with other compounds, such as low dose gemcitabine and PARP inhibitors, is warranted for HGSOC\nDr Tim Mitchell, CEO of Sareum Holdings plc, said: \"The data presented today continue to provide evidence that SRA737 has potential in ovarian cancer where the tumours exhibit defective cell cycle checkpoint control and replicative stress, and which is identifiable by genetic markers. This represents a significant proportion of HGSOC patients who currently have few treatment options. We are encouraged by the new data, which supports the rationale for Sierra's clinical study with SRA737 as a monotherapy, and look forward to updates from the ongoing clinical trials in the first half of 2019.\" \nTitle: SRA737, a novel Chk1 inhibitor, shows efficacy in CCNE1-amplified and MYCN-overexpressing high-grade serous ovarian cancer patient-derived xenograft models\nAuthors: G.Y. Ho, et al.\nThe full announcement by Sierra Oncology can be found by clicking here\nA copy of poster can be found here: http://investor.sierraoncology.com/publications \nFor further information, please contact: \n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n...